Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048364 | 1.00 | HCRTR1 (0.41) | HCRTR1HCRTR2ALDH1A1HTR1APPARG | |
| SCHEMBL3055734 | 0.92 | ALDH1A1 (0.45) | HCRTR1HCRTR2ALDH1A1HTR1APPARG | |
| SCHEMBL3046297 | 0.92 | ALDH1A1 (0.45) | HCRTR1HCRTR2ALDH1A1HTR1APPARG | |
| SCHEMBL3057175 | 0.90 | HCRTR1 (0.39) | HCRTR1HCRTR2ALDH1A1HTR1AKMT2A | |
| SCHEMBL3052731 | 0.90 | HCRTR1 (0.39) | HCRTR1HCRTR2ALDH1A1HTR1AKMT2A | |
| SCHEMBL3048360 | 0.87 | CYP3A4 (0.39) | HCRTR1HCRTR2HTR1APPARGPPARA | |
| SCHEMBL3048342 | 0.87 | CYP3A4 (0.39) | HCRTR1HCRTR2HTR1APPARGPPARA | |
| SCHEMBL3062587 | 0.87 | HCRTR1 (0.41) | HCRTR1HCRTR2ALDH1A1HTR1APPARG | |
| SCHEMBL3062719 | 0.87 | HCRTR1 (0.41) | HCRTR1HCRTR2ALDH1A1HTR1APPARG | |
| SCHEMBL3050416 | 0.86 | BACE1 (0.38) | HCRTR1HCRTR2ALDH1A1HTR1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | HCRTR1 3230/4885HCRTR2 3029/4885ALDH1A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.